Previous 10 | Next 10 |
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform t...
TRACON Pharmaceuticals, Inc. (TCON) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Charles Theuer – President and Chief Executive Officer Scott Brown – Chief Financial Officer Conference Call Participants Maury Raycroft – Jefferies Ed White ...
Tracon press release (NASDAQ:TCON): Q1 GAAP EPS of -$0.48 misses by $0.06. Cash, cash equivalents and short-term investments were $16.6 million at March 31, 2022, compared to $24.1 million at December 31, 2021. The Company expects that its current cash and cash equivalents will fund operation...
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platf...
ACOR, ADMA, APP, ASM, ASND, ASYS, ATCO, BAK, BMBL, BROS, BYND, CLPT, CLSD, CPA, CPNG, CYCC, DIS, DOX, ENVX, FLNC, FOSL, FSM, GAIN, GBDC, ICAD, KGC, LGO, LKCO, LTBR, MBII, METC, MFC, MQ, MRAM, MYO, NEON, NOAH, OCX, ONTX, OR, OTRK, PAAS, PAYS, PSTL, OTCPK:PWCDF, RIVN, SAND, SCM, SCTL, SLF, SMTS...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article is excerpted from Tom Yeung’s Moonshot Investor newsletter. To make sure you don’t miss any of Tom’s potential 100x picks, subscribe to his mailing list here . A Recession ...
SAN DIEGO, May 04, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform t...
TRACON Pharmaceuticals (NASDAQ:TCON) on Tuesday said the amended protocol to its ENVASARC trial as approved by the U.S. Food and Drug Administration (FDA) in February has been accepted at all 30 clinical sites of the trial in the U.S. and UK. TCON's ENVASARC trial is evaluating antibody envaf...
SAN DIEGO, April 19, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article is excerpted from Tom Yeung’s Moonshot Investor newsletter. To make sure you don’t miss any of Tom’s potential 100x picks, subscribe to his mailing list here . Rising Rates...
News, Short Squeeze, Breakout and More Instantly...
TRACON Pharmaceuticals Inc. Company Name:
TCON Stock Symbol:
NASDAQ Market:
TRACON Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Yoshitsu Co. Ltd (TKLF) rose 103.4% to $0.623 on volume of 309,019,720 shares Maxeon Solar Technologies Ltd. (MAXN) rose 11.2% to $0.2524 on volume of 226,231,487 shares NVIDIA Corporation (NVDA) fell 1.6% to $126.36 on volume of 208,...
A look at the top 10 most actives in the United States American Rebel Holdings Inc. (AREB) rose 60.3% to $0.83355 on volume of 56,112,820 shares DatChat Inc. (DATS) rose 71.2% to $1.78 on volume of 33,845,116 shares Autonomix Medical Inc. (AMIX) rose 97.4% to $1.22 on volume of 33,054,234...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 35.3% to $0.3248 on volume of 164,333,109 shares SRIVARU Holding Limited (SVMH) rose 62.4% to $0.2581 on volume of 68,213,933 shares NVIDIA Corporation (NVDA) rose 2.9% to $129.43 on volume o...